Acadia Pharma (ACAD) Q2 Revs of $115.2M; Tops EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
August 4, 2021 4:05 PM EDT- 2Q21 net sales of $115.2 million, a 5% increase over 2Q20
- Fiscal year 2021 revenue guidance reduced to $480 to $515 million
- Type A meeting held with FDA regarding DRP; Acadia will continue discussion with FDA in another meeting later this year
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2021.
NUPLAZID performed well in the second quarter of 2021, highlighted by our ability to drive growth while still... More
